All In Biotech

Drug Trial Radar · NCT06965413

A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity

A Randomized, Double-blind, Placebo-controlled Phase 2 Trial to Assess Efficacy, Safety, and Tolerability of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity

Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 285 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

285

Actual

Start

May 5, 2025

Primary completion

Sep 3, 2026

Study completion Mar 31, 2027

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
May 11, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main aim of the study is to assess the effect of RO7204239 in combination with tirzepatide, compared to placebo in combination with tirzepatide, on body weight loss after 48 weeks of treatment in adults with obesity or overweight with at least one weight-related comorbidity, but without diabetes mellitus (DM). The study comprises of a 4-week screening period; a 48-week core treatment period, where all participants will receive tirzepatide as background treatment and will be randomized to one of the 4 treatment arms; a 24-week treatment extension period, where participants will stop treatment with tirzepatide and a 24-week post-treatment follow-up (FU) period.

Conditions

  • Obesity
  • Overweight
  • Overweight With One Weight Related Comorbidity

Interventions

  • RO7204239Drug

    RO7204239 or matching placebo will be administered as per the schedule specified in the arms.

  • RO7204239 Matching PlaceboDrug

    RO7204239 matching placebo will be administered as per the schedule specified in the arm.

  • TirzepatideDrug

    Tirzepatide will be administered as per the schedule specified in the arms.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline in Body WeightTime frame: Baseline, Week 48

Locations

35 sites in 4 countries. Site status is shown where the registry gives one.

  • Pinnacle Research Group

    Anniston, Alabama

  • Encompass Clinical Research

    Spring Valley, California

  • K2 Medical Research-Winter Garden

    Clermont, Florida

  • Rophe Adult and Pediatric Medicine/SKYCRNG

    Union City, Georgia

  • Accellacare of Duly Health and Care

    Oak Lawn, Illinois

  • Rochester Clinical Research

    Rochester, New York

  • Accellacare of Salisbury

    Salisbury, North Carolina

  • Accellacare of Piedmont Healthcare

    Statesville, North Carolina

  • Accellacare of Wilmington, LLC

    Wilmington, North Carolina

  • Accellacare Research of Winston Salem

    Winston-Salem, North Carolina

  • NexGen Research

    Lima, Ohio

  • Accellacare of Bristol/ Internal Medicine & Pediatrics

    Bristol, Tennessee

  • Accellacare of Knoxville

    Knoxville, Tennessee

  • Clinical Research Associates

    Nashville, Tennessee

  • Texas Diabetes & Endocrinology, P.A.

    Austin, Texas

  • Juno Research, LLC

    Houston, Texas

  • Consano Clinical Research

    Shavano Park, Texas

  • Velocity Clinical Research (Impact Research Institute)

    Waco, Texas

  • Manassas Clinical Research Center

    Manassas, Virginia

  • Ekamed sp. z o.o.

    Lublin, Poland

  • ETG Warszawa

    Warsaw, Poland

  • Centrum Medyczne ALL-MED

    Krakow, Lesser Poland Voivodeship, Poland

  • Penta Hospials Badania Kliniczne Gdansk

    Gdansk, Pomeranian Voivodeship, Poland

  • Hospital Universitario Vall d'Hebron

    Barcelona, Spain

  • Hospital Universitario Virgen de la Victoria

    Málaga, Spain

  • Universidad de Sevilla - Hospital Universitario Virgen Macarena

    Seville, Barcelona, Spain

  • Instituto De Investigacion Marques De Valdecilla (IDIVAL)

    Santander, Cantabria, Spain

  • Hospital Vithas Nisa Sevilla

    Castilleja de la Cuesta, Granada, Spain

  • Hospital San Rafael A Coruna

    A Coruña, LA Coruna, Spain

  • Accellacare Warwickshire

    Coventry, United Kingdom

  • Accellacare North London

    Northwood, United Kingdom

  • Accellacare South London

    Orpington, United Kingdom

  • Fylde Coast Clinical Research at Layton Medical Centre

    Blackpool, Lancashire, United Kingdom

  • University Hospitals of Leicester NHS Trust - Leicester General Hospital (LGH)

    Leicester, Leicestershire, United Kingdom

  • Accellacare Yorkshire

    Shipley, Yorkshire, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.